BACKGROUND: Benznidazole (BNZ) is safe and effective for the treatment of paediatric Chagas disease. Treatment of adults is also effective in many cases, but discouraged in breastfeeding women because no information on BNZ transfer into breast milk is available. We aimed to evaluate the degree of BNZ transfer into breast milk in lactating women with Chagas disease. PATIENTS AND METHODS: Prospective cohort study of lactating women with Chagas disease treated with BNZ administered for 30 days. Patients and their breastfed infants were evaluated at admission, the 7th and 30th day of treatment (and monthly thereafter, for 6 months). BNZ was measured in plasma and milk by high performance liquid chromatography. The protocol was registered in ClinicalTrials.gov (#NCT01547533). RESULTS: 12 lactating women with chronic Chagas disease were enrolled (median age 28.5 years, range 20-34). Median BNZ dose was 5.65 mg/kg/day twice daily. Five mothers had adverse drug events (45%), but no adverse drug reactions or any untoward outcomes were observed in the breastfed infants. Median milk BNZ concentration was 3.8 mg/L (range 0.3-5.9) and 6.26 mg/L (range 0.3-12.6) in plasma. Median BNZ milk to plasma ratio was 0.52 (range 0.3-2.79). Median relative BNZ dose received by the infant (assuming a daily breast milk intake of 150 mL/kg/day) was 12.3% of the maternal dose per kg (range 5.5%-17%). CONCLUSIONS: The limited transference of BNZ into breast milk and the reassuring normal clinical evaluation of the breastfed babies suggest that maternal BNZ treatment for Chagas disease during breast feeding is unlikely to present a risk for the breastfed infant. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01547533. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Benznidazole (BNZ) is safe and effective for the treatment of paediatric Chagas disease. Treatment of adults is also effective in many cases, but discouraged in breastfeeding women because no information on BNZ transfer into breast milk is available. We aimed to evaluate the degree of BNZ transfer into breast milk in lactating women with Chagas disease. PATIENTS AND METHODS: Prospective cohort study of lactating women with Chagas disease treated with BNZ administered for 30 days. Patients and their breastfed infants were evaluated at admission, the 7th and 30th day of treatment (and monthly thereafter, for 6 months). BNZ was measured in plasma and milk by high performance liquid chromatography. The protocol was registered in ClinicalTrials.gov (#NCT01547533). RESULTS: 12 lactating women with chronic Chagas disease were enrolled (median age 28.5 years, range 20-34). Median BNZ dose was 5.65 mg/kg/day twice daily. Five mothers had adverse drug events (45%), but no adverse drug reactions or any untoward outcomes were observed in the breastfed infants. Median milk BNZ concentration was 3.8 mg/L (range 0.3-5.9) and 6.26 mg/L (range 0.3-12.6) in plasma. Median BNZ milk to plasma ratio was 0.52 (range 0.3-2.79). Median relative BNZ dose received by the infant (assuming a daily breast milk intake of 150 mL/kg/day) was 12.3% of the maternal dose per kg (range 5.5%-17%). CONCLUSIONS: The limited transference of BNZ into breast milk and the reassuring normal clinical evaluation of the breastfed babies suggest that maternal BNZ treatment for Chagas disease during breast feeding is unlikely to present a risk for the breastfed infant. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01547533. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Marisa L Fernández; María E Marson; Guido E Mastrantonio; Marcelo A Corti; Ulises Fleitas; Susana C Lloveras; Nicolas Lista; Maria M Priarone; Cecilia Domínguez; Facundo Garcia-Bournissen Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191
Authors: Cristina Vázquez; Elisa García-Vázquez; Bartolomé Carrilero; Marina Simón; Fuensanta Franco; Maria A Iborra; Luis J Gil-Gallardo; Manuel Segovia Journal: Am J Trop Med Hyg Date: 2020-05 Impact factor: 2.345
Authors: María L Cafferata; María A Toscani; Fernando Althabe; Jose M Belizán; Eduardo Bergel; Mabel Berrueta; Edmund V Capparelli; Álvaro Ciganda; Emmaria Danesi; Eric Dumonteil; Luz Gibbons; Pablo E Gulayin; Claudia Herrera; Jeremiah D Momper; Steven Rossi; Jeffrey G Shaffer; Alejandro G Schijman; Sergio Sosa-Estani; Candela B Stella; Karen Klein; Pierre Buekens Journal: Reprod Health Date: 2020-08-24 Impact factor: 3.223
Authors: Pamela Marie Pennington; José Guillermo Juárez; Margarita Rivera Arrivillaga; Sandra María De Urioste-Stone; Katherine Doktor; Joe P Bryan; Clara Yaseli Escobar; Celia Cordón-Rosales Journal: PLoS Negl Trop Dis Date: 2017-09-11
Authors: Luis Eduardo Echeverría; Rachel Marcus; Gabriel Novick; Sergio Sosa-Estani; Kate Ralston; Ezequiel Jose Zaidel; Colin Forsyth; Antonio Luiz P RIbeiro; Iván Mendoza; Mariano Luis Falconi; Jorge Mitelman; Carlos A Morillo; Ana Cristina Pereiro; María Jesús Pinazo; Roberto Salvatella; Felipe Martinez; Pablo Perel; Álvaro Sosa Liprandi; Daniel José Piñeiro; Gustavo Restrepo Molina Journal: Glob Heart Date: 2020-03-30